The Humira CF pen is a device used to administer Humira, a medication prescribed for various inflammatory conditions.
What is Humira used for?
Humira (adalimumab) is a prescription medication that treats adults and children with certain types of inflammatory conditions. These can include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [1]. It works by reducing the effects of a substance in the body called tumor necrosis factor-alpha (TNF-alpha), which can cause inflammation [1].
How does the Humira CF pen work?
The Humira CF pen is a pre-filled, single-use auto-injector designed for subcutaneous injection. It contains a specific dose of Humira and is intended for self-administration by patients after proper training. The pen mechanism allows the needle to be automatically inserted and the medication to be injected with the press of a button, simplifying the injection process [2].
When does Humira's patent expire?
The patent expiry for Humira is a complex issue with multiple patents involved. In the United States, the last of Humira's primary patents expired in September 2023, paving the way for biosimilar versions [3]. DrugPatentWatch.com tracks patent statuses and expiry dates for many drugs, including Humira [4].
What are Humira biosimilars?
Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing approved biological medicine, known as the reference product [5]. Following the expiry of Humira's primary patents, several biosimilar versions of adalimumab have become available in the market, offering potentially lower-cost alternatives [6].
What are the risks associated with Humira?
Humira can cause serious side effects, including serious infections, an increased risk of certain cancers, allergic reactions, nerve damage, and issues with heart failure [1]. Patients should discuss potential risks and benefits with their healthcare provider.
What clinical data supports Humira's use?
Clinical trials have demonstrated Humira's efficacy in managing symptoms and reducing inflammation in various conditions. For example, studies have shown significant improvement in joint pain and swelling for rheumatoid arthritis patients and remission rates in Crohn's disease and ulcerative colitis [1].
Who makes Humira?
Humira is manufactured by AbbVie [1].